Aduhelm - Michigan Institute for Neurological Disorders

About
Services
SERVICES

MIND provides individualized, all-in-one care to our patients, from diagnostic tests to services that treat conditions or help manage and improve symptoms, to assisting with emotional and lifestyle needs. A sampling of our services are described below.
Locations
Resources
Headache
Center
MS Center
Parkinson’s Disease
and Movement
Disorders Center
Careers

Biogen's Alzheimer’s Drug Aduhelm

**ADUHELM INFORMATION HOTLINE: 1-248-553-6214**

On Wednesday, June 16 MIND distributed the first dose in the county! Read the announcement here.

The FDA announced on Monday, June 7 its approval of Biogen’s Alzheimer’s drug Aduhelm (Aducanumab).

Aduhelm is the first disease modifying therapy approved by the FDA for certain patients with Alzheimer’s Disease (AD).

MIND is working diligently to ensure a seamless process for screening and treatment for their patients, caregivers, and referring providers.

Details are still pending Final FDA notification and payer guidance, however MIND is committed to providing up to date information as soon as possible. Please check back for updates.

Read Biogen’s news release here:

https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug

If you are interested in learning more about this treatment, please complete the form below or leave a voicemail message at 1-248-553-6214. We will get back with you as quickly as possible.

Aduhelm Inquiry

Error: Contact form not found.